Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 8,206,556
  • Shares Outstanding, K 53,870
  • Annual Sales, $ 44,820 K
  • Annual Income, $ -387,470 K
  • 36-Month Beta 1.60
  • Price/Sales 186.54
  • Price/Cash Flow 0.00
  • Price/Book 16.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.23 +14.23%
on 04/24/17
163.72 -5.65%
on 05/19/17
+18.46 (+13.57%)
since 04/21/17
3-Month
131.00 +17.92%
on 04/20/17
190.74 -19.02%
on 02/23/17
-35.47 (-18.67%)
since 02/22/17
52-Week
36.71 +320.78%
on 06/28/16
192.94 -19.94%
on 02/21/17
+111.36 (+258.32%)
since 05/20/16

Most Recent Stories

More News
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

AZN : 33.95 (+0.15%)
CLVS : 54.44 (+4.21%)
TSRO : 154.47 (+1.40%)
RHHBY : 34.4300 (+0.39%)
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc's (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe...

TSRO : 154.47 (+1.40%)
TESARO Announces Approval of VARUBY(R) (Oral Rolapitant Tablets) by European Commission

-- VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimen

TSRO : 154.47 (+1.40%)
TESARO Announces Approval of VARUBY(R) (Oral Rolapitant Tablets) by European Commission

- VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimen

TSRO : 154.47 (+1.40%)
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017

TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference...

TSRO : 154.47 (+1.40%)
Tesaro Announces Participation in Two Investor Conferences

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:

TSRO : 154.47 (+1.40%)
Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULA(TM) (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by TESARO, Inc. to be a specialty pharmacy provider in the distribution network...

TSRO : 154.47 (+1.40%)
US Bioservices selected by TESARO to dispense ZEJULA (niraparib)

US Bioservices, an independent specialty pharmacy and part of AmerisourceBergen, announced today it has been selected by TESARO, Inc. as a specialty pharmacy partner for ZEJULA(TM) (niraparib)....

ABC : 89.48 (+0.36%)
TSRO : 154.47 (+1.40%)
Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma

On Tuesday, April 11, 2017, US markets saw a mixed session as 2 sectors closed in green, 4 sectors finished in red, and 3 sectors ended flat for the day. Major US indices were bearish at the close of yesterday's...

CRBP : 6.55 (+1.55%)
ALNY : 73.93 (+3.15%)
TSRO : 154.47 (+1.40%)
INO : 7.09 (-1.12%)
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE) Awards. Pharma/Biotech Product Development Team of the Year...

TSRO : 154.47 (+1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor...

See More

Support & Resistance

2nd Resistance Point 158.83
1st Resistance Point 156.65
Last Price 154.47
1st Support Level 150.93
2nd Support Level 147.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.